Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults With PTSD

Machine-Learning Training Study of the Senseye Diagnostic Tool for Diagnosis of Adults With Post-Traumatic Stress Disorder (PTSD), Anxiety, and Depression

The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms. The study will also collect data on Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) to aid in assessing the presence and severity of these disorders both for the purpose of discerning them from PTSD and determining the feasibility of diagnosing them independently.

Study Overview

• Status: Recruiting
• Conditions: PTSD; Generalized Anxiety Disorder; Major Depressive Disorder
• Intervention / Treatment: Diagnostic test: Senseye DT; Diagnostic test: CAPS-5-R

Detailed Description

This clinical study will be conducted to inform and train the Senseye DT's machine learning algorithm, to be evaluated in a future study for effectiveness in identifying people with PTSD compared to the Clinician-Administered PTSD Scale for DSM-5, revised version (CAPS-5-R) assessment. The Senseye DT is designed to utilize video data captured from a subject's eyes while they are presented various visual stimuli to extract ocular metrics (i.e., pupil size, gaze pattern, etc.) and heart rate data and use this information to detect the presence and severity of PTSD. Due to the overlapping symptomatology between PTSD, GAD, and MDD and common elements of ANS abnormalities (e.g., hyperarousal in both PTSD and GAD), it is necessary for the Senseye DT's specificity to discern between PTSD, GAD and MDD. This study is therefore designed to fully assess the presence and severity of each of these disorders in subjects to ensure device specificity as well as to test the feasibility to diagnose and rate severity of these conditions.

The study will be divided into two concurrent phases:

Phase I will focus on assessing the presence of PTSD via Screening through Baseline Study Visits. The objective of this phase is to obtain an accurate baseline diagnosis and severity rating for PTSD using Standard of Care methods and to use the Senseye DT to obtain data necessary for the device to be trained to produce a PTSD diagnosis. Baseline diagnosis and severity of GAD and MDD will also be determined.

Phase II will focus on assessing the severity of PTSD symptoms over time, with the objective to collect data necessary to train the Senseye DT machine learning algorithm to accurately determine a subject's PTSD severity rating correlated to the CAPS-5-R. Phase II consists of follow-up time points of 4 weeks, 8 weeks, and 12 weeks, and assesses changes in PTSD since the baseline severity determined in Phase I. Changes in GAD and MDD from baseline will also be assessed.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Brad Strasser, RAC; Phone Number: 512-524-6970; Email: brad.strasser@senseye.co
• Study Contact Backup: Name: David Zakariaie; Email: david@senseye.co

Study Locations

• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Not yet recruiting
      • University of Colorado Anschutz Medical Campus
      • Contact: Blair Bacon; Phone Number: 720-739-0581; Email: blair.bacon@cuanschutz.edu
      • Principal Investigator: Steven Berkowitz, MD
  • Idaho
    • Meridian, Idaho, United States, 83642
      • Recruiting
      • Velocity Clinical Research
      • Contact: Daniel Korsgaard, RA; Phone Number: 242 208-377-8653; Email: dkorsgaard@velocityclinical.com
      • Principal Investigator: Esther Huffine, MSN, NP-C
  • South Carolina
    • Charleston, South Carolina, United States, 29401
      • Recruiting
      • Ralph H. Johnson VA Health Care System
      • Principal Investigator: Ronald Acierno, PhD
      • Contact: Ronald Acierno, PhD; Phone Number: 843-789-6519
  • Texas
    • Dallas, Texas, United States, 75231
      • Recruiting
      • Future Search Trials
      • Contact: Michael J Downing, M.D.; Phone Number: 214-361-7700
    • Edinburg, Texas, United States, 78539
      • Recruiting
      • DHR Health Institute for Research and Development
      • Contact: Esmeralda Cardoso-Mendoza; Phone Number: 956-362-2391; Email: e.cardoso@dhr-rgv.com
      • Principal Investigator: Adrian Agapito, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adults with or without PTSD, Generalized Anxiety Disorder (GAD), and/or Major Depressive Disorder (MDD)

Description

Inclusion Criteria:

1. Willing and able to read, understand, and sign the IRB-approved Informed Consent Form.
2. Age 18+.
3. Study groups: Diagnosed with PTSD, GAD, and/or MDD.
4. Control groups: Not diagnosed with PTSD, GAD, or MDD.
5. Deemed likely to comply with the study protocol, including willing communication of adverse events (AEs), mental health treatment history, current and past psychiatric medication, and ability to attend all study follow-up visits.
6. Medically stable as determined by the clinician or investigator.
7. Virtual sites: Subject has access to a stable internet and WIFI connection and an iPhone 11 or newer.

Exclusion Criteria:

1. Psychotic or self-injurious behavior.
2. Current diagnosis of epilepsy and/or other current seizure disorders.
3. A history of or positive at screening for bipolar I or II, mania, or one or more schizophrenia-spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, delusional disorder, and psychosis.
4. Compromised facial neuro-ophthalmic integrity (e.g., due to stroke, MS, ALS, or other neurological conditions).
5. Current diagnosis of dementia, delirium, amnestic disorders, autism, hydrocephalus, posterior cortical atrophy, aphasia, multiple sclerosis, or stroke-related cognitive dysfunction.
6. Current eye disorders which prevent the patient from using the Senseye DT (complete list in full protocol).
7. Active suicidal and/or homicidal intent which may put the participant and/or others at risk per the investigator's clinical judgement, or has suicidal ideation with intent to act within 6 months prior to the start of the screening phase as determined by a C-SSRS score > 3, or history of suicidal behavior within the past year prior to the start of the screening phase.
8. Current reported usage (within 2 weeks of Initial Study Visit and/or planned ongoing usage during the study) of psychotropic and/or non-psychotropic drugs/medication which may affect use of the Senseye DT (complete list in full protocol).
9. Current reported usage (within 2 weeks of Initial Study Visit and/or planned ongoing usage during the study) of vagal nerve stimulation, deep brain stimulation, transcranial magnetic stimulation, or electroconvulsive therapy.
10. Any condition which precludes the ability for subjects to safely and accurately complete clinical assessments, questionnaires, or to follow instructions necessary to administer the Senseye DT (e.g., significant developmental disabilities, language disorders, cognitive deficiencies, or other neurodevelopmental disorders).
11. Traumatic Brain Injury (TBI) within the last 12 months.
12. Lifetime history of any of the following: surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's Disease, Parkinson's Disease), epilepsy, mental retardation, or any other disease/procedure/accident/intervention that, according to the clinician, is deemed associated with significant injury to, or malfunction of, the CNS.
13. Pregnant or intending on becoming pregnant during the duration of the study as determined by self-report.
14. Currently incarcerated.
15. Participant requires a legal guardian to consent.

Study Plan

How is the study designed?

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
PTSD positive; Subjects meet criteria for PTSD, with or without comorbid Generalized Anxiety Disorder or Major Depressive Disorder	Diagnostic test: Senseye DT; Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.; Diagnostic test: CAPS-5-R; A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.; Other Names: Clinician-Administered Scale for PTSD for DSM-5, Revised version
Primary GAD; Subjects DO NOT meet criteria for PTSD, but meet criteria for Generalized Anxiety Disorder	Diagnostic test: Senseye DT; Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.; Diagnostic test: CAPS-5-R; A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.; Other Names: Clinician-Administered Scale for PTSD for DSM-5, Revised version
Primary MDD; Subjects DO NOT meet criteria for PTSD, but meet criteria for Major Depressive Disorder	Diagnostic test: Senseye DT; Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.; Diagnostic test: CAPS-5-R; A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.; Other Names: Clinician-Administered Scale for PTSD for DSM-5, Revised version
Comorbid GAD/MDD; Subjects DO NOT meet criteria for PTSD, but meet criteria for Generalized Anxiety Disorder and Major Depressive Disorder	Diagnostic test: Senseye DT; Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.; Diagnostic test: CAPS-5-R; A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.; Other Names: Clinician-Administered Scale for PTSD for DSM-5, Revised version
Trauma-positive, PTSD/GAD/MDD-negative; Subjects have trauma exposure meeting DSM-5-TR Criterion A, but DO NOT meet criteria for PTSD, GAD, or MDD	Diagnostic test: Senseye DT; Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.; Diagnostic test: CAPS-5-R; A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.; Other Names: Clinician-Administered Scale for PTSD for DSM-5, Revised version
Trauma-negative; Subjects DO NOT have trauma exposure meeting DSM-5-TR Criterion A and DO NOT meet criteria for PTSD, GAD, or MDD	Diagnostic test: Senseye DT; Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agreement between Senseye DT and CAPS-5-R assessment at baseline	The Senseye DT demonstrates a statistically significant difference (p<0.05) of ocular signal and/or heart rate data between subjects with PTSD and/or GAD and/or MDD and control subjects at Baseline. Senseye DT results and clinical assessment diagnosis results will be compared using a 2-sample t-test or Wilcoxon rank-sum test.	Baseline
Agreement between Senseye DT and CAPS-5-R at 12 weeks	The Senseye DT demonstrates a statistically significant difference (p<0.05) of ocular signal and/or heart rate data between subjects with PTSD and/or GAD and/or MDD and control subjects at the 12-week follow-up time point. Senseye DT results and clinical assessment diagnosis results will be compared using a 2-sample t-test or Wilcoxon rank-sum test.	12 weeks
Establishment of Ground Truth - PTSD	To obtain data using the Senseye DT measures in both PTSD and control subjects to establish a "ground truth" for the Senseye DT's machine learning algorithm to use for objectively diagnosing and ranking severity of PTSD.	Baseline & 12 weeks
Establishment of Ground Truth - GAD/MDD	To obtain data using the Senseye DT to establish a "ground truth" for the Senseye DT's machine learning algorithm to use for objectively diagnosing and ranking severity of GAD and/or MDD.	Baseline & 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Administer Tool	The Senseye DT demonstrates significantly less time to administer than the CAPS-5-R, based on actual recorded time for study staff to administer each assessment. Senseye DT time and CAPS-5-R time will be compared using a 2-sample t-test or Wilcoxon rank-sum test.	Baseline & 12 weeks

Collaborators and Investigators

• Sponsor: Senseye, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2023
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: January 28, 2023
• First Submitted That Met QC Criteria: January 28, 2023
• First Posted (Actual): February 8, 2023

Study Record Updates

• Last Update Posted (Estimated): November 3, 2023
• Last Update Submitted That Met QC Criteria: November 2, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Depressive Disorder; Anxiety Disorders; Depressive Disorder, Major
• Other Study ID Numbers: CSP-PT-0003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No